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Introduction: Identifying patients at high risk of developing kidney disease could
lead to early clinical interventions that prevent or slow disease progression. Soluble
urokinase plasminogen activator receptor (suPAR) is an inflammatory biomarker
thought to be involved in the pathogenesis and development of kidney disease.
We aimed to determine whether elevated plasma suPAR measured at hospital
admission is associated with incident kidney disease in patients presenting to the
emergency department.
Materials and Methods: This was a retrospective registry-based cohort study
performed at the Emergency Department of Copenhagen University Hospital Amager
and Hvidovre, Hvidovre, Denmark. Patients were included in the study from November
2013 to March 2017 and followed until June 2017. Patients were excluded if they
were diagnosed with kidney disease or died prior to index discharge. Plasma suPAR
was measured at hospital admission, and the main outcome was time to incident
kidney disease, defined by ICD-10 diagnosis codes for both chronic and acute kidney
conditions. Association between suPAR and time to incident kidney disease was
assessed by Cox proportional hazard regression analysis.
Results: In total, 25,497 patients (median age 58.1 years; 52.5% female) were admitted
to the emergency department and followed for development of kidney disease. In
multivariable Cox regression analysis adjusting for age, sex, eGFR, CRP, cardiovascular
disease, hypertension, and diabetes, each doubling in suPAR at hospital admission was
associated with a hazard ratio of 1.57 (95% CI: 1.38–1.78, P < 0.001) for developing
a chronic kidney condition and 2.51 (95% CI: 2.09–3.01, P < 0.001) for developing an
acute kidney condition.
Discussion: In a large cohort of acutely hospitalized medical patients, elevated suPAR
was independently associated with incident chronic and acute kidney conditions. This
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highlights the potential for using suPAR in risk classification models to identify high-risk
patients who could benefit from early clinical interventions. The main limitation of this
study is its reliance on accurate reporting of ICD-10 codes for kidney disease.
Keywords: chronic kidney disease, acute kidney injury, dialysis, soluble urokinase plasminogen activator
receptor, glomerular filtration rate, emergency department
INTRODUCTION
Chronic kidney disease (CKD) is a major health issue affecting
8–16% of people worldwide (Jha et al., 2013). Patients with
CKD have increased rates of cardiovascular disease, end-stage
renal disease (ESRD), hospitalization, and death (Go et al., 2004;
Astor et al., 2011; Gansevoort et al., 2013). Identifying patients
at high risk of developing CKD may lead to earlier medical
interventions that reduce morbidity and mortality associated
with disease progression (James et al., 2010; Akbari et al., 2014).
However, current measures of kidney function, such as estimated
glomerular filtration rate (eGFR) and proteinuria, are insensitive
predictors of incident kidney disease (Levey et al., 2009; James
et al., 2010; Eloot et al., 2011).
Soluble urokinase plasminogen activator receptor (suPAR) is
an endogenous signaling molecule and biomarker of chronic
inflammation, and elevated suPAR levels have been associated
with a range of diseases and mortality (Eugen-Olsen et al.,
2010). In 2015, suPAR was described as a novel biomarker for
eGFR decline and CKD in a cohort of cardiovascular patients
(Hayek et al., 2015). Subsequent studies have replicated these
results in healthy middle-aged participants (Schulz et al., 2017),
patients with type 1 diabetes (Curovic et al., 2019), and children
(Schaefer et al., 2017). Another study demonstrated that high
suPAR in patients undergoing cardiac surgery was a risk factor for
postoperative acute kidney injury (Mossanen et al., 2017). There
is growing evidence that suPAR may reflect the pathogenesis of
kidney disease, and it has been proposed that suPAR itself causes
kidney disease by damaging renal podocytes (Wei et al., 2011;
Hayek et al., 2017).
Patients admitted through the emergency department are
characterized by high age and disease burden (Juul-Larsen et al.,
2017), and they are at elevated baseline risk of developing kidney
disease after discharge (Rohun et al., 2011). Routine suPAR
measurements in such high-risk patient populations may help
identify patients at highest risk of developing kidney disease
and ultimately lead to clinical interventions that slow or prevent
disease progression. Therefore, we tested the hypothesis that
elevated suPAR measured at hospital admission is associated with
the development of kidney disease.
MATERIALS AND METHODS
Study Design and Setting
This was a retrospective observational cohort study performed
at Copenhagen University Hospital Amager and Hvidovre. The
initial patient population included all patients admitted to the
Acute Medical Unit of the Emergency Department between
November 18, 2013 and March 17, 2017 with follow-up data
accessible in the Danish National Patient Registry (DNPR).
Index admission was defined as the first recorded admission
with a suPAR measurement within this study period. Patients
were excluded from analysis if they were diagnosed with kidney
disease, received dialysis, or died from any cause prior to index
discharge. Patients with prior urolithiasis were not excluded. Data
on prior kidney disease was obtained from the DNPR dating back
to 1977. The study was approved by the Danish Data Protection
Agency (ref. HVH-2014-018, 02767) and the Danish Health and
Medicines Authority (ref. 3-3013-1061/1).
Measurements
Demographic information including age and sex was obtained
from the Civil Registration System. Chronic disease status
including cardiovascular disease, hypertension, and diabetes
was described by two-year history of chronic diseases based
on International Classification of Disease (ICD)-10 diagnosis
codes from the DNPR (Supplementary Table S1). Blood
samples were collected on admission to the Acute Medical
Unit, and a standard panel of markers, including creatinine,
C-reactive protein (CRP), and suPAR, was analyzed as part of
routine evaluation at the Department of Clinical Biochemistry.
Creatinine was measured on a Roche Cobas R© c8000 701/702
(Roche Diagnostics, Mannheim, Germany) with a module
instrument using the Roche Creatinine Plus version 2 IDMS-
traceable enzymatic assay. CRP was measured on a Roche Cobas R©
6000 (Roche Diagnostics, Mannheim, Germany). suPAR was
measured on a Siemens BEP2000 using the suPARnostic R© AUTO
Flex ELISA (ViroGates A/S, Birkerød, Denmark) according to the
manufacturer’s instructions. Estimated GFR was calculated with
the creatinine-based equation from the Chronic Kidney Diseases
Epidemiology Collaboration (CKD-EPI) (Inker et al., 2012).
Outcomes
Information about disease status, hospital readmissions, and
death was collected during a follow-up period beginning at
index discharge and extending to a censor date (June 17, 2017)
90 days after the last patient was included (median follow-
up time 755 days; range 90–1,307 days). Patients who left
the country during the study period were censored at their
last recorded hospitalization. Disease status during the study
period was determined by ICD-10 codes obtained from the
DNPR, which compiles information from all inpatient and
outpatient activity within the Danish secondary healthcare
system (Lynge et al., 2011). The quality of information
within the DNPR has been described elsewhere (Schmidt
et al., 2015). Kidney disease was defined as any ICD-
10 diagnosis, procedure, or operation code suggesting renal
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impairment (Supplementary Table S2). Kidney diseases were
categorized as chronic kidney condition (CKD, glomerular disease,
tubulointerstitial disease, or other renal disorder) or acute kidney
condition (acute dialysis or acute kidney injury). Information
on vital status at the end of follow-up was obtained from the
Civil Registration System. The primary outcome was time to
event during follow-up, which was defined as number of days
from index discharge to first kidney disease diagnosis or death
(whichever came first).
Statistics
Patient characteristics are presented with basic statistics:
continuous variables as median with interquartile range,
and discrete variables as number with percent of patients.
Comparison between included and excluded patients was
assessed by Wilcoxon rank sum test. Association between suPAR
and incident kidney disease was assessed by Cox proportional
hazard regression analysis and graphically represented by
cumulative incidence plots. Association between suPAR and
all-cause mortality was assessed by Cox proportional hazard
regression analysis and graphically represented by a Kaplan-
Meier plot.
An initial Cox regression model was generated with suPAR
quartile as the explanatory variable and incident chronic kidney
condition, acute kidney condition, or death as the endpoint.
Start date was set to day of index discharge, censor date
was set to June 17, 2017, and all endpoints were modeled as
competing events for all other endpoints. Next, the analysis was
repeated with suPAR modeled as a continuous variable. This was
done first as a univariate model with log2(suPAR) as the sole
explanatory variable and then as a multivariate model adjusted
for age, sex, log2(eGFR), log10(CRP), cardiovascular disease,
hypertension, and diabetes. In these models, suPAR, eGFR, and
CRP were log-transformed for the purpose of interpretation
and comparison with previous studies (Rasmussen et al., 2016;
Rasmussen et al., 2018). Collinearity between log2(suPAR) and
the covariates was assessed by variance inflation factor (VIF),
and VIF greater than 5 was considered an indication of
collinearity (Sheather, 2009). Association between log2(suPAR)
and log2(eGFR) was further assessed by linear regression, and
normality of residuals was evaluated by QQ-plot. Given the
known association between suPAR and eGFR, an additional
sensitivity analysis removing patients with eGFR less than
60 mL/min/1.73 m2 was performed for the multivariate models.
For a similar reason, sensitivity analysis removing patients with
prior diagnosis of cardiovascular disease was also performed for
the multivariate models.
To investigate differences in hazard ratio for specific etiologies
of chronic kidney conditions, the continuous Cox regression
models were repeated for these endpoints subdivided by disease
type (CKD, glomerular disease, tubulointerstitial disease, or
other renal disorder). To investigate differences in hazard
ratio for specific etiologies of acute kidney conditions, the
continuous Cox regression models were repeated for these
endpoints subdivided by specific time periods from index
discharge to diagnosis (<30 days, 30–90 days, or >90 days).
In these time period specific models, patients who were
censored or developed an event before each time period
were excluded from the model for that time period, and
patients who were censored or developed an event after each
time period were censored at the end of that time period.
Proportional hazard assumption of each regression model was
evaluated by Schoenfeld residuals. P < 0.05 was taken to be
statistically significant. SAS Enterprise Guide 7.1 (SAS Institute
Inc, Cary, NC, United States) was used for statistical analysis and
generation of figures.
RESULTS
Study Cohort
In total, 29,088 patients with follow-up data had suPAR measured
at hospital admission during the study period. Of these, 2,836
patients were excluded due to prior kidney disease and 755
additional patients were excluded due to death from any cause
prior to index discharge, resulting in a study cohort of 25,497
acute medical patients (Supplementary Figure S1). Baseline
characteristics at index admission for the study cohort are
shown in Table 1. Median age was 58.1 years, and 52.5% of
patients were female. Compared with patients excluded due to
prior kidney disease (n = 2,836), the study cohort had higher
median eGFR (88.7 vs. 56.7 mL/min/1.73 m2), lower median
CRP (4.0 vs. 16.0 mg/L), and lower median suPAR (2.7 vs. 4.5
ng/mL) (all P < 0.001). Compared with patients excluded for
any reason (n = 3,591), the study cohort had higher median
eGFR (88.7 vs. 57.4 mL/min/1.73 m2), lower median CRP (4.0
vs. 26.0 mg/L), and lower median suPAR (2.7 vs. 4.9 ng/mL)
(all P < 0.001).
Outcomes During Follow-Up
During the follow-up period, 760 patients (3.0%) developed
kidney disease, and 3,199 patients (12.5%) died without being
diagnosed with kidney disease. Among patients who developed
incident kidney disease, 570 patients (75%) developed a chronic
kidney condition, and 190 patients (25%) developed an acute
kidney condition (Table 1). Patients who developed kidney
disease or died were older, had more comorbid conditions, more
readmissions, lower eGFR, higher CRP, and higher suPAR at
index admission compared with patients who were censored at
follow-up. Basic statistics for patients developing each type of
kidney condition are shown in Table 2. Among incident chronic
kidney conditions, CKD was the most common diagnosis (263
cases), tubulointerstitial disease was the next most common
(185 cases), and glomerular disease was the least common
(23 cases). Among incident acute kidney conditions, 24 cases
(12.6%) occurred within 30 days of index discharge, 29 cases
(15.3%) occurred within 30–90 days, and 137 cases (72.1%)
occurred after 90 days.
Association of suPAR With eGFR
There was no indication of collinearity between log2(suPAR)
and the covariates, with the largest variance inflation for age
(VIF 1.82) and log2(eGFR) (VIF 1.74). However, there was a
significant association between log2(suPAR) and log2(eGFR) at
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TABLE 1 | Patient characteristics by outcome.
All patients
N = 25,497
Incident chronic
kidney condition
n = 570
Incident acute
kidney condition
n = 190
Death without
kidney disease
n = 3,199
No event (censor)
n = 21,538
Demographics
Age in years, median (IQR) 58.1 (40.3–73.7) 72.5 (58.2–81.8) 68.5 (56.3–77.0) 79.4 (69.2–87.2) 54.0 (37.4–69.6)
Female, n (%) 13,373 (52.5%) 265 (46.5%) 73 (38.4%) 1,697 (53.0%) 11,338 (52.6%)
Chronic disease status
Hypertension, n (%) 2,745 (10.8%) 131 (23.0%) 38 (20.0%) 624 (19.5%) 1,952 (9.1%)
Cardiovascular disease, n (%) 2,534 (9.9%) 123 (21.6%) 35 (18.4%) 745 (23.3%) 1,631 (7.6%)
Chronic pulmonary disease, n (%) 2,160 (8.5%) 67 (11.8%) 36 (18.9%) 595 (18.6%) 1,462 (6.8%)
Diabetes, n (%) 1,601 (6.3%) 108 (18.9%) 44 (23.2%) 362 (11.3%) 1,087 (5.0%)
Cancer, n (%) 1,291 (5.1%) 42 (7.4%) 11 (5.8%) 653 (20.4%) 585 (2.7%)
Dementia, n (%) 505 (2.0%) 13 (2.3%) 3 (1.6%) 264 (8.3%) 225 (1.0%)
Liver disease, n (%) 362 (1.4%) 11 (1.9%) 11 (5.8%) 76 (2.4%) 264 (1.2%)
Peptic ulcer disease, n (%) 226 (0.9%) 11 (1.9%) 5 (2.6%) 54 (1.7%) 156 (0.7%)
Othera, n (%) 465 (1.8%) 19 (3.3%) 8 (4.2%) 100 (3.1%) 338 (1.6%)
Hospital admission
Received surgery during hospitalization, n (%) 230 (0.9%) 3 (0.5%) 2 (1.1%) 24 (0.8%) 201 (0.9%)
Length of stay in days, median (IQR) 1 (0–3) 2 (1–6) 2 (1–7) 3 (1–8) 1 (0–2)
Acute readmission during follow-up:
Within 30 days, n (%) 3,911 (15.3%) 154 (27.0%) 64 (33.7%) 1,119 (35.0%) 2,574 (12.0%)
Within 90 days, n (%) 6,058 (23.8%) 251 (44.0%) 101 (53.2%) 1,596 (49.9%) 4,110 (19.1%)
Biomarkers
eGFR in mL/min/1.73 m2, median (IQR)b 88.7 (69.8–104.7) 54.0 (36.3–84.6) 72.6 (49.7–93.2) 69.8 (50.0–87.7) 91.5 (74.7–106.7)
<60 mL/min/1.73 m2, n (%) 3,987 (16.4%) 311 (57.2%) 68 (37.0%) 1,180 (38.2%) 2,428 (11.8%)
≥60 mL/min/1.73 m2, n (%) 20,323 (83.6%) 233 (42.8%) 116 (63.0%) 1,908 (61.8%) 18,066 (88.2%)
CRP in mg/L, median (IQR)b 4 (1–22) 10 (3–50) 9 (3–55) 19 (5–70) 4 (1–15)
suPAR in ng/mL, median (IQR)b 2.7 (2.0–3.9) 4.2 (2.9–5.8) 4.6 (3.1–6.3) 4.5 (3.3–6.2) 2.5 (1.9–3.5)
a Includes connective tissue disease, paraplegia/hemiplegia, and HIV/AIDS. bMeasured at index admission; 1,187 patients (4.7%) missing value for eGFR and C-reactive
protein. CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; IQR, interquartile range; suPAR, soluble urokinase plasminogen activator receptor.
TABLE 2 | Association of log2(suPAR) with development of incident chronic and acute kidney conditions.
Endpoint No. patients Median (IQR) eGFRa
(mL/min/1.73 m2)
Median (IQR)a
suPAR (ng/mL)
Hazard Ratio (95% CI)b
Univariate Multivariatec
Chronic kidney condition 570 54.0 (36.3–84.6) 4.2 (2.9–5.8) 2.52 (2.31–2.75) 1.57 (1.38–1.78)
Chronic kidney disease 263 41.2 (30.6–58.4) 4.8 (3.6–6.3) 3.20 (2.84–3.60) 1.77 (1.47–2.13)
Glomerular disease 23 73.1 (52.8–98.0) 3.2 (2.0–5.8) 1.64 (1.00–2.67) 1.13 (0.60–2.14)
Tubulointerstitial disease 185 82.7 (56.8–107.0) 3.2 (2.2–4.6) 1.56 (1.31–1.86) 1.26 (1.00–1.59)
Other renal disorder 99 47.0 (33.6–71.5) 4.6 (3.5–6.3) 2.99 (2.46–3.65) 2.07 (1.56–2.76)
Acute kidney condition 190 72.6 (49.7–93.2) 4.6 (3.1–6.3) 2.96 (2.57–3.42) 2.51 (2.09–3.01)
<30 days from index 24 75.1 (59.3–93.5) 4.7 (3.9–6.3) 2.99 (2.01–4.44) 2.43 (1.45–4.06)
30–90 days from index 29 74.6 (54.0–93.6) 5.0 (3.1–7.4) 2.96 (2.06–4.26) 2.67 (1.70–4.20)
>90 days from index 137 69.9 (47.2–92.9) 4.6 (2.9–6.2) 2.96 (2.50–3.51) 2.49 (2.01–3.09)
aMeasured at index admission; 1,187 patients (4.7%) missing value for eGFR. bHazard ratios represent the proportional risk of developing the given kidney condition for
each doubling in suPAR and is evaluated for the entire duration of follow-up unless otherwise specified. cAdjusted for age, sex, log2(eGFR), log10(CRP), cardiovascular
disease, hypertension, and diabetes. CI, confidence interval; eGFR, estimated glomerular filtration rate; IQR, interquartile range; suPAR, soluble urokinase plasminogen
activator receptor.
index admission, with β = –0.32 (Supplementary Figure S2).
Patients with eGFR<60 mL/min/1.73 m2 had significantly higher
suPAR compared to patients with eGFR >60 mL/min/1.73 m2
(median 4.5 vs 2.5 ng/mL, P < 0.001). Among patients with
eGFR >60 mL/min/1.73 m2, 349 patients (1.7%) developed
kidney disease, and 1,908 patients (9.4%) died during
follow-up. Among patients with eGFR <60 mL/min/1.73 m2,
379 patients (9.5%) developed kidney disease, and 1,180
patients (29.6%) died during follow-up. For all categories of
eGFR, patients who developed kidney disease or died during
Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 June 2020 | Volume 8 | Article 339
fcell-08-00339 June 11, 2020 Time: 20:42 # 5
Iversen et al. suPAR and Incident Kidney Disease
FIGURE 1 | Cumulative incidence of chronic kidney conditions (A) and acute kidney conditions (B) by suPAR quartile. Shaded areas indicate 95% confidence
intervals.
follow-up had significantly higher suPAR at index admission
(Supplementary Figure S3).
Association of suPAR With Chronic
Kidney Conditions
Cumulative incidence of chronic kidney conditions by suPAR
quartile is shown in Figure 1A. Compared with patients in the
lowest suPAR quartile, patients in the 2nd quartile had a hazard
ratio of 1.65 (95% CI: 1.15–2.37, P = 0.007) for developing an
incident chronic kidney condition, patients in the 3rd quartile
had a hazard ratio of 2.77 (95% CI: 1.99–3.86, P < 0.001), and
patients in the highest suPAR quartile had a hazard ratio of 8.53
(95% CI: 6.31–11.54, P < 0.001).
Modeling suPAR as a continuous variable, each doubling in
suPAR yielded an unadjusted hazard ratio of 2.52 (95% CI: 2.31–
2.75, P < 0.001) and an adjusted hazard ratio of 1.57 (95% CI:
1.38–1.78, P < 0.001) for developing an incident chronic kidney
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FIGURE 2 | Survival by suPAR quartile. Shaded areas indicate 95%
confidence intervals.
condition (Table 2). Sensitivity analysis removing patients with
eGFR <60 mL/min/1.73 m2 resulted in an adjusted hazard ratio
of 1.43 (95% CI: 1.17–1.73, P < 0.001), and sensitivity analysis
removing patients with a prior diagnosis of cardiovascular disease
resulted in an adjusted hazard ratio of 1.53 (95% CI: 1.33–1.77,
P < 0.001) for developing an incident chronic kidney condition.
Association of suPAR With Acute Kidney
Conditions
Cumulative incidence of acute kidney conditions by suPAR
quartile is shown in Figure 1B. Compared with patients in the
lowest suPAR quartile, patients in the 2nd quartile had a hazard
ratio of 4.83 (95% CI: 1.82–12.82, P = 0.002) for developing an
incident acute kidney condition, patients in the 3rd quartile had
a hazard ratio of 10.43 (95% CI: 4.14–26.23, P < 0.001), and
patients in the highest suPAR quartile had a hazard ratio of 30.47
(95% CI: 12.44–74.67, P < 0.001).
Modeling suPAR as a continuous variable, each doubling in
suPAR yielded an unadjusted hazard ratio of 2.96 (95% CI:
2.57–3.42, P < 0.001) and an adjusted hazard ratio of 2.51
(95% CI: 2.09–3.01, P < 0.001) for developing an incident
acute kidney condition (Table 2). Sensitivity analysis removing
patients with eGFR <60 mL/min/1.73 m2 resulted in an adjusted
hazard ratio of 2.68 (95% CI: 2.17–3.32, P < 0.001), and
sensitivity analysis removing patients with a prior diagnosis of
cardiovascular disease resulted in an adjusted hazard ratio of 2.45
(95% CI: 2.01–3.00, P < 0.001) for developing an incident acute
kidney condition.
Association of suPAR With All-Cause
Mortality
Survival by suPAR quartile is shown in Figure 2. Compared with
patients in the lowest suPAR quartile, patients in the 2nd quartile
had a hazard ratio of 3.17 (95% CI: 2.54–3.96, P < 0.001) for
dying during follow-up, patients in the 3rd quartile had a hazard
ratio of 7.99 (95% CI: 6.53–9.79, P < 0.001), and patients in
the highest suPAR quartile had a hazard ratio of 23.23 (95% CI:
19.10–28.24, P < 0.001).
Modeling suPAR as a continuous variable, each doubling in
suPAR yielded an unadjusted hazard ratio of 2.89 (95% CI: 2.79–
3.00, P < 0.001) and an adjusted hazard ratio of 1.99 (95% CI:
1.89–2.09, P < 0.001) for dying during follow-up. Sensitivity
analysis removing patients with eGFR <60 mL/min/1.73 m2
resulted in an adjusted hazard ratio of 2.02 (95% CI: 1.90–2.15,
P < 0.001), and sensitivity analysis removing patients with a
prior diagnosis of cardiovascular disease resulted in an adjusted
hazard ratio of 2.01 (95% CI: 1.89–2.13, P < 0.001) for dying
during follow-up.
DISCUSSION AND CONCLUSION
In a cohort of 25,497 acutely hospitalized medical patients
without prior kidney disease, we found that elevated suPAR
at hospital admission was significantly associated with higher
incidence of kidney disease and all-cause mortality during
a median follow-up of 2 years. These associations were
independent of age, sex, eGFR, CRP, cardiovascular disease,
hypertension, and diabetes at index admission. In the adjusted
model, each doubling in suPAR increased the hazard of
developing an incident chronic kidney condition by 57%
and the hazard of developing an incident acute kidney
condition by 151%.
Our study cohort had notably lower median suPAR
(2.7 ng/mL) than what has been reported by similar studies
in the emergency department, such as the 2016 TRIAGE III
trial in Denmark that reported median suPAR of 4.1 ng/mL
(Schultz et al., 2018). This can be explained in part by our
selection criteria. Patients with prior kidney disease or who
died during index admission had higher median suPAR than
the initial patient population, so their exclusion resulted in
a study cohort with lower median suPAR (Supplementary
Figure S1). Differences in the assays used to measure
suPAR may also contribute to variations in suPAR values.
A recent study comparing the assay used by our hospital
(suPARnostic R© AUTO Flex ELISA) to another common
assay (Quantikine R© Human uPAR-Immunoassay) found that
suPARnostic R© yielded significantly lower suPAR in healthy
controls and higher suPAR in patients with kidney disease
(Winnicki et al., 2019).
While suPAR has previously been associated with kidney
disease (Hayek et al., 2015; Mossanen et al., 2017; Schaefer
et al., 2017; Schulz et al., 2017; Curovic et al., 2019), this is
the first study to our knowledge to evaluate the association
among patients in the emergency department. This is an
important patient population to consider because these patients
tend to be older and have multiple comorbid conditions
(Juul-Larsen et al., 2017), putting them at greater risk of
post-hospitalization kidney disease. Our results from a large
population of acute medical patients suggest suPAR as a
candidate to include in prediction models for kidney disease.
If patients can be classified based on risk of developing kidney
disease, then closer monitoring and early interventions in high
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risk patients may slow kidney disease progression and avoid
complications related to renal dysfunction. For example, a
2009 study from Sweden found that one third of all adverse
drug reactions leading to hospitalization in older patients
were related to improper dose adjustment according to renal
function (Helldén et al., 2009), emphasizing the importance
of medication review for patients at risk of developing
impaired renal function.
In 2013, our hospital began measuring suPAR as a routine
biomarker in the emergency department. For acute medical
patients, we have previously reported that elevated suPAR
at hospital admission is associated with increased rates of
surgery (Meyer et al., 2018), future readmission (Rasmussen
et al., 2016), and all-cause mortality independent of presenting
symptoms (Rasmussen et al., 2018). However, while suPAR
has been implicated in many medical conditions, its causal
mechanisms have only been investigated in kidney disease.
It is believed that formation of a complex between suPAR
and αvβ3-integrin (a surface receptor on renal podocytes) can
alter podocyte shape and disrupt the kidney’s ability to retain
large proteins such as albumin (Hayek et al., 2017). We did
not find that elevated suPAR was associated more strongly
with kidney diseases affecting podocyte function, but this does
not exclude the possibility that suPAR may directly contribute
to kidney damage.
It may be suggested that suPAR is simply a sensitive
filtration marker for early kidney damage, as suPAR is freely
filtered by the kidneys and can be measured in the urine.
However, we found that the association of suPAR with incident
kidney disease remained significant even after adjustment
for eGFR, suggesting that elevated suPAR also reflects a
feature of kidney disease separate from decreased filtration.
Another possibility is that suPAR is related to a systemic
chronic inflammatory state. It is well established that chronic
inflammation may be responsible for insidious tissue damage
(Furman et al., 2019), and elevated suPAR is associated with
multiple organ failure and sepsis (Patrani et al., 2016; Zeng
et al., 2016). Therefore, high suPAR may indicate a state of
chronic low-grade inflammation that predisposes a patient to
kidney damage. We adjusted for CRP in our analysis, but
CRP is a marker of acute inflammation and likely produced
through an inflammatory pathway separate from that of suPAR
(Lyngbæk et al., 2013).
In any case, our results in the context of current literature
clearly indicate that suPAR is related to aspects of kidney
function that are unexplained by current kidney biomarkers.
If suPAR is involved in kidney disease pathogenesis, then
interventions to reduce suPAR could potentially prevent disease
progression in high-risk patients. Haupt et al. (2019) found that
current lifestyle as well as changes to diet, smoking, alcohol
use, and exercise impacted suPAR over a five-year period,
and suPAR levels attained at the end of this period were
predictive of follow-up mortality. This finding demonstrates that
suPAR is a modifiable risk factor, but it is unknown whether
initiatives to reduce suPAR in humans would also reduce the
incidence of kidney disease. More recently, Hayek et al. (2020)
observed that suPAR overexpression in mice led to acute kidney
injury, and pretreatment with uPAR antibody attenuated this
injury. This is the latest evidence to suggest a causative role
of suPAR in kidney disease as well as identify a potential
therapeutic target.
The strength of our study is its large population size.
Copenhagen University Hospital Amager and Hvidovre was the
first hospital to implement routine suPAR measurements for all
acute medical patients, affording us a head start in investigating
the role of systemic chronic inflammation in disease progression.
Furthermore, since the DNPR contains information about all
hospital encounters, we were able to obtain follow-up medical
records for >99% of patients in our initial cohort. The collection
of routine suPAR measurements and unique access to national
registry data enabled us to investigate the association between
suPAR and specific disease diagnoses over a four-year period in
a large patient cohort.
The main limitation of our study is its reliance on ICD-
10 diagnosis codes for both the exclusion criteria and primary
outcome of kidney disease. However, a 2011 study found high
positive predictive value of ICD-10 codes for renal disease within
the DNPR (Thygesen et al., 2011), and a 2013 study concluded
that registration of acute admissions within the DNPR has high
validity (Vest-Hansen et al., 2013). Still, discrepancies between
kidney disease prevalence and diagnosis within Denmark
indicate that kidney disease is likely underreported in the
DNPR (Henriksen et al., 2018). This discrepancy may be
even greater for patients admitted through the emergency
department, since clinicians sometimes only record the primary
discharge diagnosis.
Ideally, our registry data would be supported by repeated
measurements of both eGFR and proteinuria, as well as results
of kidney biopsy. Current guidelines from Kidney Disease
Improving Global Outcomes (KDIGO) define CKD as eGFR
<60 mL/min/1.73 m2 or albuminuria >30 mg/day for a
period of >3 months (Levin and Stevens, 2014). The lack of
these endpoints within our cohort is an important limitation
in the assessment of CKD, and our results rely largely on
the accurate reporting of kidney disease in the DNPR. To
address this issue, we performed a sensitivity analysis removing
patients with eGFR <60 mL/min/1.73 m2 and obtained similar
results. However, using a single creatinine measurement to
identify kidney disease is inaccurate and does not always
reflect a patient’s full clinical picture (Levey et al., 2015).
For example, other conditions such as cardiovascular disease
(Liu et al., 2014), hypertension (Lindeman et al., 1984), and
diabetes (Alicic et al., 2017) are known to affect long-term
kidney function. Therefore, we attempted to control for these
conditions by including them in our analysis as potential
confounders. We also performed a sensitivity analysis removing
patients with known cardiovascular disease and obtained
similar results.
In conclusion, we found that elevated suPAR in acute medical
patients was independently associated with incident chronic
and acute kidney conditions, as well as all-cause mortality.
We propose suPAR as a candidate biomarker to include in
risk classification models for kidney disease. Future studies are
needed to evaluate whether early interventions in high risk
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patients can slow disease progression or avoid complications
related to renal dysfunction.
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